Enliven Therapeutics Q3 net loss $20.8M; cash $263.5M; ELVN-001/002 data on track for 2024

Enliven Therapeutics, Inc.

2023-Q3 EPS reported -$1.55

Cash, cash equivalents and marketable securities of $263.5M as of Sept 30, 2023; expected runway into early 2026.
Net loss $20.8M vs $10.6M in Q3 2022; R&D expense $19.6M (up from $7.8M); G&A $4.6M (up from $3.1M).
ELVN-001 (CML) and ELVN-002 (HER2-altered solid tumors) Phase 1 trials enrolling; initial proof-of-concept data expected in 2024.
Third IND-enabling study completed; additional pipeline details and guidance planned for H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Enliven Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $20.8 million.

Period: the third quarter ended September 30, 2023
Net income: $20.8 million
Result: reported results

Exact text from the filing

Enliven reported a net loss of $20.8 million for the third quarter of 2023

View on SEC.gov

Browse all earnings releases →

Enliven Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-062042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.